Evidence map›Paper›PMID 42121345›Full record

ReviewJournal of cellular and molecular medicine2026

AP-1-Targeting Decoy Oligonucleotides: Mechanisms and Therapeutic Potential as Modulators of Inflammatory Pathways.

Maryam Mahjoubin-Tehran, Samaneh Rezaei, Vasily N Sukhorukov, Amin Jalili, Prashant Kesharwani, Amirhossein Sahebkar

Abstract readReview
In one paragraph

Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maryam Mahjoubin-TehranSchool of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Samaneh RezaeiDepartment of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Vasily N SukhorukovInstitute of General Pathology and Pathophysiology, Moscow, Russia.
Amin JaliliDepartment of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Prashant KesharwaniNext-Generation Translational Nanomedicine Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India.ORCID 0000-0002-0890-769X
Amirhossein SahebkarBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID 0000-0002-8656-1444

Funding

Russian Science Foundation 25-15-00269
6 · The paper itself

Abstract

Numerous cellular functions, such as apoptosis, proliferation, differentiation, survival, transformation and cell migration, are regulated by a crucial transcription factor called activator protein 1 (AP-1). Growing evidence indicates that AP-1 is involved in severe conditions like fibrosis, cancer, and organ damage, as well as inflammatory diseases, including rheumatoid arthritis, psoriasis, and asthma. In recent years, AP-1 has become a significant focus in drug research. The activation of AP-1 by TNF is crucial for essential components of the inflammatory reaction, including the expression of tissue remodelling proteases such as collagenase, as well as pro-inflammatory cell adhesion molecules like E-selectin. This transcription factor is formed by the assembly of jun-jun homodimers, jun-fos heterodimers, and jun-ATF (Activating Transcription Factor) heterodimers. As a member of the basic leucine zipper (bZIP) class, AP-1 regulates target genes by binding to their promoters in a sequence-specific way. New research suggests that reducing AP-1 function could improve various disease outcomes and treatments. Transfection of decoy oligonucleotides (ODNs) offers an innovative approach to gene therapy by targeting specific gene regulatory elements. Transcription factor decoys mimic the sites where transcription factors bind, competing with promoter regions within the cell nucleus. These molecules can regulate interactions between DNA sequences and transcription factors, which play a role in altering gene activation during both normal and disease-related cellular processes. This review aims to summarize the effects of AP-1-targeted decoys on various conditions. The studies demonstrated the great promising role of AP-1 decoys as therapeutics for various diseases, especially cardiovascular diseases and cancers. Moreover, it was shown that modifications of AP-1 (circular and hairpin as well as phosphorothioate backbones structures) decoys made them more stable and effective.

Indexed as

InflammationOligonucleotidesTranscription Factor AP-1AnimalsHumansNeoplasmsSignal TransductionOligonucleotidesTranscription Factor AP-1AP‐1cancercardiovascular diseasedecoyoligonucleotidestranscription factors

Identifiers

PMID42121345
PMCPMC13167699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.